Rheumatoid Arthritis Prevention and Treatment: My Top Studies From EULAR 2020
  • CME

June 3-6, 2020; Virtual Meeting
My take on the most important findings in RA prevention and treatment presented at the virtual EULAR 2020 E-Congress.
Paul Emery, MA, MD, FRCP
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: July 16, 2020 Expiration: July 15, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify emerging therapies for RA and potential applications to RA management

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Paul Emery, MA, MD, FRCP

Versus Arthritis, Professor of Rheumatology 
Leeds Institute of Rheumatic & Musculoskeletal Medicine
University of Leeds
Consultant, Rheumatology
Leeds Teaching Hospitals NHS Trust
Leeds, West Yorkshire

Paul Emery, MA, MD, FRCP, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, Lilly, and Novartis.

Staff

Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatologists, primary care clinicians, and other healthcare providers who care for patients with RA.

Goal

The goal of this activity is to arm clinicians with the most current clinical and scientific advances in RA so that they can apply the latest evidence to optimally manage patients and achieve long-term remission.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 16, 2020, through July 15, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

New from EULAR 2020: risk of venous thromboembolism (DVT or PE) varies by DAS28 in patients with rheumatoid arthritis as reported by Clinical Care Options (CCO)

Released: August 13, 2020

New from EULAR 2020, Clinical Care Options (CCO): adults with immune-mediated inflammatory disease report biologic-associated fatigue in Dutch Biologic Monitor

Released: August 13, 2020

Expert commentary on key studies on safety and efficacy of JAK inhibitors from EULAR 2020 as reported by CCO

Eric M. Ruderman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: July 16, 2020 Expired: July 15, 2021

From EULAR 2020, 52-week analysis of FINCH 1 trial of add-on filgotinib in rheumatoid arthritis with inadequate methotrexate response, by CCO

Released: July 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?